Craft

AbbVie

Stock Price

$170.8

2024-06-25

Market Capitalization

$301.5 B

2024-06-25

Revenue

$54.3 B

FY, 2023

AbbVie Summary

Company Summary

Overview
AbbVie is a pharmaceutical company engaged in the research and development, manufacturing, commercialization, and sale medicines and therapies. Its products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and HIV; neurological disorders, such as Parkinson's disease; metabolic diseases; hormonal disorders; in pulmonology such as idiopathic pulmonary fibrosis and cystic fibrosis; and other health conditions. The company sells its products directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers.
Type
Public
Status
Active
Founded
2013
HQ
Lake Bluff, IL, US | view all locations
Website
https://www.abbvie.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Richard A. Gonzalez

    Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer

  • Rae L. Livingston

    Rae L. Livingston, Chief Equity Officer

  • Scott T. Reents

    Scott T. Reents, Executive Vice President, Chief Financial Officer

  • Timothy J. Richmond

    Timothy J. Richmond, Executive Vice President, Chief Human Resources Officer

Operating MetricsView all

Countries

70

FY, 2022

Manufacturing Facilities

19

FY, 2022

Research and Development Centers

14

FY, 2020

LocationsView all

63 locations detected

  • Lake Bluff, IL HQ

    United States

    1 Waukegan Rd

  • Cambridge, MA

    United States

    200 Sidney St

  • Mettawa, IL

    United States

    26525 Riverwoods Blvd

  • North Chicago, IL

    United States

    1401 Sheridan Rd

  • Washington, DC

    United States

    1399 New York Ave NW #600

  • Worcester, MA

    United States

    100 Research Dr

and 57 others

AbbVie Financials

Summary Financials

Revenue (Q1, 2024)
$12.3B
Gross profit (Q1, 2024)
$8.2B
Net income (Q1, 2024)
$1.4B
Cash (Q1, 2024)
$18.1B
EBIT (Q1, 2024)
$2.8B
Enterprise value
$357.5B

Footer menu